← Back to Search

Biospecimen Collection for Peritoneal Cancer

N/A
Recruiting
Led By Maheswari Senthil, MD FACS
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is researching the causes of gastrointestinal cancer. Patients provide blood, tumor samples, and fluids for study.

Who is the study for?
This trial is for adults over 18 with peritoneal carcinomatosis originating from gastrointestinal tumors, who are scheduled for standard surgical procedures. They must be able to understand and sign consent forms. Those unable to follow the study protocol cannot participate.
What is being tested?
The study involves collecting biospecimens such as blood, ascites/peritoneal wash fluid, and tumor samples during planned surgeries of patients with gastrointestinal peritoneal carcinomatosis.
What are the potential side effects?
Since this trial focuses on sample collection rather than drug testing, there are no direct side effects related to medications. However, typical risks associated with surgical procedures may apply.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT)
Establishment of angioarchitechture of peritoneal lesions through Optical Coherence Tomography Angiography (OCTA)
Secondary study objectives
Compare response of therapeutic regimens in a pdPC VMT to the observed clinical response (by RECIST criteria or diagnostic laparoscopy)
Overall Survival (OS)
Progression-Free Survival (PFS) at 6 months

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Subjects with Gastrointestinal Primary Tumor with or without Peritoneal CarcinomatosisExperimental Treatment1 Intervention
Subjects with gastrointestinal (GI) primary tumor with or without peritoneal carcinomatosis who are undergoing planned standard of care (SOC) surgical procedures. Biospecimens such as blood, peritoneal wash fluid and tumor samples will be obtained.

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
564 Previous Clinical Trials
1,932,576 Total Patients Enrolled
Maheswari Senthil, MD FACSPrincipal InvestigatorChao Family Comprehensive Cancer Center

Media Library

Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis Clinical Trial Eligibility Overview. Trial Name: NCT05844865 — N/A
Abdominal Cancer Research Study Groups: Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis
Abdominal Cancer Clinical Trial 2023: Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis Highlights & Side Effects. Trial Name: NCT05844865 — N/A
Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis 2023 Treatment Timeline for Medical Study. Trial Name: NCT05844865 — N/A
~11 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top